A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11150%2F18%3A10382641" target="_blank" >RIV/00216208:11150/18:10382641 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00179906:_____/18:10382641
Výsledek na webu
<a href="https://www.ncbi.nlm.nih.gov/pubmed/29755669" target="_blank" >https://www.ncbi.nlm.nih.gov/pubmed/29755669</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.18632/oncotarget.24980" target="_blank" >10.18632/oncotarget.24980</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer
Popis výsledku v původním jazyce
Biomarker analysis has become routine practice in the treatment of non-small cell lung cancer (NSCLC). To ensure high quality testing, participation to external quality assessment (EQA) schemes is essential. This article provides a longitudinal overview of the EQA performance for EGFR, ALK, and ROS1 analyses in NSCLC between 2012 and 2015. The four scheme years were organized by the European Society of Pathology according to the ISO 17043 standard. Participants were asked to analyze the provided tissue using their routine procedures. Analysis scores improved for individual laboratories upon participation to more EQA schemes, except for ROS1 immunohistochemistry (IHC). For EGFR analysis, scheme error rates were 18.8%, 14.1% and 7.5% in 2013, 2014 and 2015 respectively. For ALK testing, error rates decreased between 2012 and 2015 by 5.2%, 3.2% and 11.8% for the fluorescence in situ hybridization (FISH), FISH digital, and IHC subschemes, respectively. In contrast, for ROS1 error rates increased between 2014 and 2015 for FISH and IHC by 3.2% and 9.3%. Technical failures decreased over the years for all three markers. Results show that EQA contributes to an ameliorated performance for most predictive biomarkers in NSCLC. Room for improvement is still present, especially for ROS1 analysis.
Název v anglickém jazyce
A stitch in time saves nine: external quality assessment rounds demonstrate improved quality of biomarker analysis in lung cancer
Popis výsledku anglicky
Biomarker analysis has become routine practice in the treatment of non-small cell lung cancer (NSCLC). To ensure high quality testing, participation to external quality assessment (EQA) schemes is essential. This article provides a longitudinal overview of the EQA performance for EGFR, ALK, and ROS1 analyses in NSCLC between 2012 and 2015. The four scheme years were organized by the European Society of Pathology according to the ISO 17043 standard. Participants were asked to analyze the provided tissue using their routine procedures. Analysis scores improved for individual laboratories upon participation to more EQA schemes, except for ROS1 immunohistochemistry (IHC). For EGFR analysis, scheme error rates were 18.8%, 14.1% and 7.5% in 2013, 2014 and 2015 respectively. For ALK testing, error rates decreased between 2012 and 2015 by 5.2%, 3.2% and 11.8% for the fluorescence in situ hybridization (FISH), FISH digital, and IHC subschemes, respectively. In contrast, for ROS1 error rates increased between 2014 and 2015 for FISH and IHC by 3.2% and 9.3%. Technical failures decreased over the years for all three markers. Results show that EQA contributes to an ameliorated performance for most predictive biomarkers in NSCLC. Room for improvement is still present, especially for ROS1 analysis.
Klasifikace
Druh
J<sub>SC</sub> - Článek v periodiku v databázi SCOPUS
CEP obor
—
OECD FORD obor
30109 - Pathology
Návaznosti výsledku
Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2018
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Oncotarget
ISSN
1949-2553
e-ISSN
—
Svazek periodika
9
Číslo periodika v rámci svazku
29
Stát vydavatele periodika
US - Spojené státy americké
Počet stran výsledku
15
Strana od-do
20524-20538
Kód UT WoS článku
—
EID výsledku v databázi Scopus
2-s2.0-85045521709